We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
BRNS

Price
0.84
Stock movement down
-0.03 (-3.32%)
Company name
Barinthus Biotherapeutics plc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
34.25M
Ent value
-
Price/Sales
-
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-50.23%
3 year return
-41.49%
5 year return
-
10 year return
-
Last updated: 2025-08-27

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

BRNS does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.92
Daily high0.93
Daily low0.82
Daily Volume28K
All-time high17.00
1y analyst estimate4.50
Beta-0.72
EPS (TTM)-
Dividend per share-
Ex-div date-
Next earnings date6 Nov 2025

Downside potential

Loading...
Downside potential data
BRNSS&P500
Current price drop from All-time high-95.05%-3.04%
Highest price drop-96.15%-56.47%
Date of highest drop23 May 20259 Mar 2009
Avg drop from high-72.17%-11.04%
Avg time to new high115 days12 days
Max time to new high1029 days1805 days

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
BRNS (Barinthus Biotherapeutics plc) company logo
Marketcap
34.25M
Marketcap category
Small-cap
Description
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent high-risk human papillomavirus; VTP-850, an immunotherapeutic candidate for prostate cancer; VTP-600, an immunotherapeutic candidate targeting MAGE-A3 and NY-ESO1 antigens; VTP-500, a prophylactic vaccine candidate to prevent middle east respiratory syndrome; VTP-400, a prophylactic vaccine candidate for shingles; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.
Employees
105
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...